Binding of Antitumor Ruthenium(III) Complexes to Plasma Proteins
Author Information
Author(s): L. Messori, F. Gonzales Vilchez, R. Vilaplana, F. Piccioli, E. Alessio, B. Keppler
Primary Institution: Department of Chemistry, University of Florence
Hypothesis
The binding of selected antitumor ruthenium(III) complexes to plasma proteins will significantly impact their biodistribution and pharmacokinetics.
Conclusion
Antitumor ruthenium(III) complexes bind tightly to plasma proteins, which may influence their therapeutic effectiveness.
Supporting Evidence
- Ruthenium(III) complexes bind plasma proteins tightly, especially at imidazole groups.
- Binding occurs at the iron binding site of transferrin and involves slow kinetics.
- NAMI A, a ruthenium complex, binds tightly to bovine serum albumin, indicating potential in vivo relevance.
- RAP, another ruthenium complex, shows similar binding characteristics to various plasma proteins.
Takeaway
This study shows that certain cancer-fighting drugs made from ruthenium stick to proteins in our blood, which might change how they work in the body.
Methodology
The study used separation and spectroscopic techniques to analyze the interactions of ruthenium(III) complexes with plasma proteins.
Limitations
The study primarily focuses on in vitro interactions, which may not fully represent in vivo behavior.
Want to read the original?
Access the complete publication on the publisher's website